Lung cancer (non-small-cell) - pemetrexed (maintenance) (TA190)
Fast, easy summary view of NICE guidance on 'lung cancer'
Specific, concise statements that act as markers of high-quality, cost-effective patient care
What has NICE said?
NICE recommends pemetrexed as a possible maintenance treatment for some people with non-small-cell lung cancer (see below).
Who can have pemetrexed?
You should be able to have pemetrexed if all the following apply:
- you have locally advanced or metastatic non-small-cell lung cancer
- squamous cell carcinoma is not the main type of cancer you have
- you have not received pemetrexed and cisplatin together as a first treatment
- your condition did not worsen immediately after you received platinum-based chemotherapy together with gemcitabine, paclitaxel or docetaxel.
Why has NICE said this?
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life. NICE recommended pemetrexed because the cost was justified by the benefits it provided when the special considerations were applied.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: lung cancer
This page was last updated: 08 May 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA190 Pemetrexed fel triniaeth gynnal ar gyfer canser yr ysgyfaint lle nad yw'r celloedd yn fach: deall canllawiau NICE (fformat MS Word)
Information for the public
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.